Difference between revisions of "Azacitidine (Vidaza)"
(Created page with "==General information== Class/mechanism: Pyrimidine nucleoside analog of cytidine, causes hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bo...") |
|||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
Class/mechanism: Pyrimidine nucleoside analog of cytidine, causes hypomethylation of DNA and direct cytotoxicity on abnormal | Class/mechanism: Pyrimidine nucleoside analog of cytidine, causes hypomethylation of DNA and direct cytotoxicity on abnormal | ||
− | hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation.<ref name="insert">[http://www.vidaza.com/pdf/PI_FINAL.pdf Azacitidine (Vidaza) package insert]</ref><ref>[http://hemonc.org/docs/ | + | hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation.<ref name="insert">[http://www.vidaza.com/pdf/PI_FINAL.pdf Azacitidine (Vidaza) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/azacitidine.pdf Azacitidine (Vidaza) package insert (locally hosted backup)]</ref> |
<br>Route: IV/SC | <br>Route: IV/SC | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== |
Revision as of 16:30, 29 November 2011
General information
Class/mechanism: Pyrimidine nucleoside analog of cytidine, causes hypomethylation of DNA and direct cytotoxicity on abnormal
hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation.[1][2]
Route: IV/SC
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)